Chris Seeger Appointed to the Humira MDL Executive Committee

Seeger Weiss founding partner, Chris Seeger, has been appointed to the MDL Executive Committee of pending antitrust litigation against drug maker AbbVie for the company’s action regarding popular immune drug, Humira. A number of lawsuits against AbbVie and other pharmaceutical companies have been brought by insurance clients and other end-payers due to accusations that the […]

June 7, 2019

Chris Seeger headshot

Seeger Weiss founding partner, Chris Seeger, has been appointed to the MDL Executive Committee of pending antitrust litigation against drug maker AbbVie for the company’s action regarding popular immune drug, Humira.

A number of lawsuits against AbbVie and other pharmaceutical companies have been brought by insurance clients and other end-payers due to accusations that the companies engaged in unfair competitive acts regarding Humira and its related patents. These cases have been consolidated into multidistrict litigation (MDL) in the U.S. District Court for the Northern District of Illinois under Judge Manish S. Shah.

Judge Shah has appointed Seeger Weiss founding partner, Chris Seeger to the Executive Committee for the Humira MDL. The MDL Executive Committee is comprised of nine attorneys which includes three co-lead counsels from New York, California and Massachusetts and six plaintiff’s executive committee members from Louisiana, New York, Pennsylvania, and California.

The lawsuits claim that AbbVie engaged in improper anti-competitive action to protect its market exclusivity of autoimmune drug Humira. The lawsuits have been brought by insurance and managed care payers who may have been improperly forced to pay higher costs for Humira versus similar medications which were blocked from the U.S. market.

Humira is a flagship drug of AbbVie and brings the company over $20 billion per year in revenue. It is used for a number of autoimmune disorders including Rheumatoid Arthritis and is the best-selling medication of its type. Outside of the U.S., Humira faces competition from biosimilar medications but AbbVie has been successful in preventing U.S. competition with a web of over 100 patents that surround the medication.

Related News

June 7, 2024
Seeger Weiss Receives Highest Honors in 2024 Chambers Guide

Seeger Weiss is proud to announce that the firm, alongside partners Chris Seeger and Dave Buchanan, has been recognized in Band 1 for Product Liability: Plaintiffs in the newly released Chambers 2024 USA Guide. Additionally, partner Benjamin Barnett has been recognized for his contributions to E-Discovery & Information Governance. For more than 30 years, Chambers […]

Read More
May 24, 2024
Lawdragon Names Nine Seeger Weiss Partners to 500 Plaintiff Financial Lawyers List

Seeger Weiss is proud to announce that Lawdragon recognized nine partners — Chris Seeger, Stephen Weiss, David Buchanan, Shauna Itri, Jennifer Scullion, Chris Ayers, Ben Barnett, Parvin Aminolroaya, and Steve Daroci — on the 2024 500 Leading Plaintiff Financial Lawyers list. This guide, first published in 2007 by Lawdragon Inc., presents Lawdragon’s opinion of “the […]

Read More
May 13, 2024
Seeger Weiss, Chris Seeger Named Elite Trial Lawyers Plaintiff Firm of the Year and Plaintiff Attorney of the Year Finalists; Parvin Aminolroaya Wins Elite Women of the Plaintiffs Bar Award

Seeger Weiss is pleased to announce that the firm and several of its partners have won or are finalists for multiple 2024 National Law Journal Elite Trial Lawyers Awards. Seeger Weiss was named a finalist for: Plaintiffs Firm of the Year Environmental Protection Practice Group of the Year Government Representation Practice Group of the Year […]

Read More